Novan, a late-stage biotech developing nitric oxide therapies for acne and other skin conditions, raised $45 million by offering 4.1 million shares at $11. It originally intended to raise $45 million by offering 3.75 million shares at a range of $11 to $13. Novan plans to list on the Nasdaq under the symbol NOVN. Piper Jaffray acted as a lead manager on the deal.
